These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 10232611)

  • 1. Tumor spectrum in ARF-deficient mice.
    Kamijo T; Bodner S; van de Kamp E; Randle DH; Sherr CJ
    Cancer Res; 1999 May; 59(9):2217-22. PubMed ID: 10232611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled atm function.
    Kamijo T; van de Kamp E; Chong MJ; Zindy F; Diehl JA; Sherr CJ; McKinnon PJ
    Cancer Res; 1999 May; 59(10):2464-9. PubMed ID: 10344759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of Bax alters tumor spectrum and tumor numbers in ARF-deficient mice.
    Eischen CM; Rehg JE; Korsmeyer SJ; Cleveland JL
    Cancer Res; 2002 Apr; 62(7):2184-91. PubMed ID: 11929842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways.
    Kelly-Spratt KS; Gurley KE; Yasui Y; Kemp CJ
    PLoS Biol; 2004 Aug; 2(8):E242. PubMed ID: 15314658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
    Eischen CM; Weber JD; Roussel MF; Sherr CJ; Cleveland JL
    Genes Dev; 1999 Oct; 13(20):2658-69. PubMed ID: 10541552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis.
    Inoue K; Wen R; Rehg JE; Adachi M; Cleveland JL; Roussel MF; Sherr CJ
    Genes Dev; 2000 Jul; 14(14):1797-809. PubMed ID: 10898794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development.
    Eischen CM; Alt JR; Wang P
    Oncogene; 2004 Nov; 23(55):8931-40. PubMed ID: 15467748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cooperativity of p19ARF, Mdm2, and p53 in murine tumorigenesis.
    Moore L; Venkatachalam S; Vogel H; Watt JC; Wu CL; Steinman H; Jones SN; Donehower LA
    Oncogene; 2003 Oct; 22(49):7831-7. PubMed ID: 14586409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation.
    Lin AW; Lowe SW
    Proc Natl Acad Sci U S A; 2001 Apr; 98(9):5025-30. PubMed ID: 11309506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.
    Eischen CM; Roussel MF; Korsmeyer SJ; Cleveland JL
    Mol Cell Biol; 2001 Nov; 21(22):7653-62. PubMed ID: 11604501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice.
    McDonnell TJ; Montes de Oca Luna R; Cho S; Amelse LL; Chavez-Reyes A; Lozano G
    J Pathol; 1999 Jul; 188(3):322-8. PubMed ID: 10419603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased Mdm2 expression inhibits tumor development induced by loss of ARF.
    Wang P; Greiner TC; Lushnikova T; Eischen CM
    Oncogene; 2006 Jun; 25(26):3708-18. PubMed ID: 16491126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of p14ARF overcomes tumor resistance to p53.
    Lu W; Lin J; Chen J
    Cancer Res; 2002 Mar; 62(5):1305-10. PubMed ID: 11888896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2.
    Kamijo T; Weber JD; Zambetti G; Zindy F; Roussel MF; Sherr CJ
    Proc Natl Acad Sci U S A; 1998 Jul; 95(14):8292-7. PubMed ID: 9653180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53-independent functions of the p19(ARF) tumor suppressor.
    Weber JD; Jeffers JR; Rehg JE; Randle DH; Lozano G; Roussel MF; Sherr CJ; Zambetti GP
    Genes Dev; 2000 Sep; 14(18):2358-65. PubMed ID: 10995391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF.
    Jacobs JJ; Scheijen B; Voncken JW; Kieboom K; Berns A; van Lohuizen M
    Genes Dev; 1999 Oct; 13(20):2678-90. PubMed ID: 10541554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of nevi and skin tumors in Ink4a/Arf Xpa knockout mice by neonatal, intermittent, or chronic UVB exposures.
    van Schanke A; van Venrooij GM; Jongsma MJ; Banus HA; Mullenders LH; van Kranen HJ; de Gruijl FR
    Cancer Res; 2006 Mar; 66(5):2608-15. PubMed ID: 16510579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of neurofibromatosis-1 and p19(ARF) cooperate to induce a multiple tumor phenotype.
    King D; Yang G; Thompson MA; Hiebert SW
    Oncogene; 2002 Jul; 21(32):4978-82. PubMed ID: 12118376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization.
    Rizos H; Darmanian AP; Mann GJ; Kefford RF
    Oncogene; 2000 Jun; 19(26):2978-85. PubMed ID: 10871849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis.
    Sharpless NE; Bardeesy N; Lee KH; Carrasco D; Castrillon DH; Aguirre AJ; Wu EA; Horner JW; DePinho RA
    Nature; 2001 Sep; 413(6851):86-91. PubMed ID: 11544531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.